EVOLUS, INC. (EOLS) Operating Margin
- Operating margin · 12 months: Value -5.90%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -5.90% | Operating income / revenue. Period ending 2026-06-30. $-18.67M ÷ $316.49M × 100 ≈ -5.90% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -18.67M USD | Operating Income (Loss) |
| Revenue | 316.49M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 105.28M USD | Cost of Goods and Services Sold |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | 216.50M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-18.67M | $316.49M | $105.28M | (m) | $216.50M | -5.90% |
| 2026-03-31 | $-24.34M | $301.79M | $102.44M | (m) | $216.13M | -8.06% |
| 2025-12-31 | $-32.66M | $297.18M | $100.07M | (m) | $220.79M | -10.99% |
| 2025-09-30 | $-39.20M | $285.82M | $95.37M | (m) | $216.38M | -13.71% |
| 2025-06-30 | $-43.17M | $277.94M | $91.23M | (m) | $216.06M | -15.53% |
| 2025-03-31 | $-40.66M | $275.46M | $87.01M | (m) | $209.54M | -14.76% |
| 2024-12-31 | $-34.41M | $266.27M | $83.97M | (m) | $198.03M | -12.92% |
| 2024-09-30 | $-40.73M | $248.33M | $74.64M | (m) | $190.84M | -16.40% |
| 2024-06-30 | $-38.70M | $237.26M | $71.84M | (m) | $181.66M | -16.31% |
| 2024-03-31 | $-46.12M | $219.70M | $67.48M | (m) | $172.68M | -20.99% |
| 2023-12-31 | $-49.23M | $202.09M | $61.56M | (m) | $164.94M | -24.36% |
| 2023-09-30 | $-51.23M | $184.73M | $55.66M | (m) | $158.62M | -27.73% |
| 2023-06-30 | $-55.69M | $168.61M | $53.72M | (m) | $150.08M | -33.03% |
| 2023-03-31 | $-61.92M | $156.43M | $54.83M | (m) | $145.78M | -39.58% |
| 2022-12-31 | $-65.33M | $148.62M | $55.89M | (m) | $141.84M | -43.96% |
| 2022-09-30 | $-72.72M | $139.63M | $58.35M | (m) | $138.38M | -52.08% |
| 2022-06-30 | $-73.93M | $132.41M | $56.35M | (m) | $135.26M | -55.84% |
| 2022-03-31 | $-67.88M | $121.34M | $51.83M | $1.69M | $124.84M | -55.94% |
| 2021-12-31 | $-44.41M | $99.67M | $43.53M | $2.06M | $112.07M | -44.55% |
| 2021-09-30 | $-134.44M | $85.59M | $34.98M | $2.36M | $106.23M | -157.06% |
| 2021-06-30 | $-124.07M | $76.58M | $28.34M | $2.41M | $96.49M | -162.03% |
| 2021-03-31 | $-127.66M | $58.28M | $18.99M | $2.06M | $87.57M | -219.03% |
| 2020-12-31 | $-153.07M | $56.54M | $18.30M | $1.72M | $98.19M | -270.73% |
| 2020-09-30 | $-57.59M | $55.41M | $14.66M | $1.42M | $101.08M | -103.93% |
| 2020-06-30 | $-73.96M | $50.92M | $13.52M | $1.76M | $110.03M | -145.26% |
| 2020-03-31 | $-91.07M | $45.42M | $12.23M | $2.13M | $127.37M | -200.51% |
| 2019-12-31 | $-98.95M | $34.92M | $8.01M | $3.97M | $113.59M | -283.31% |
| 2019-09-30 | $-98.91M | (m) | (m) | $4.74M | (m) | (m) |
| 2019-06-30 | $-85.26M | (m) | (m) | $6.02M | (m) | (m) |
| 2019-03-31 | $-65.37M | (m) | (m) | $7.16M | (m) | (m) |
| 2018-12-31 | $-46.14M | (m) | (m) | $6.49M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-11.73M | (m) | (m) | $6.69M | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |